Bosh sahifaMEHCQ • OTCMKTS
add
23andMe Holding Co
Yopilish kursi
4,24 $
Kunlik diapazon
4,05 $ - 4,39 $
Yillik diapazon
0,47 $ - 10,81 $
Bozor kapitalizatsiyasi
117,60 mln USD
Oʻrtacha hajm
575,71 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
OTCMKTS
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | mar, 2025info | Y/Y qiyosi |
---|---|---|
Daromad | 45,15 mln | -29,49% |
Joriy xarajat | 65,51 mln | -34,62% |
Sof foyda | -99,35 mln | 52,43% |
Sof foyda marjasi | -220,04 | 32,54% |
Har bir ulushga tushum | — | — |
EBITDA | -45,06 mln | 35,08% |
Amaldagi soliq stavkasi | 0,00% | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | mar, 2025info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 38,25 mln | -82,33% |
Jami aktivlari | 159,89 mln | -59,54% |
Jami passivlari | 186,64 mln | -9,68% |
Umumiy kapital | -26,74 mln | — |
Tarqatilgan aksiyalar | 27,54 mln | — |
Narxi/balansdagi bahosi | -4,37 | — |
Aktivlardan daromad | -54,88% | — |
Kapitaldan daromad | -230,70% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | mar, 2025info | Y/Y qiyosi |
---|---|---|
Sof foyda | -99,35 mln | 52,43% |
Operatsiyalardan naqd pul | -40,73 mln | -57,97% |
Sarmoyadan naqd pul | -734,00 ming | 65,80% |
Moliyadan naqd pul | -529,00 ming | -126,45% |
Naqd pulning sof oʻzgarishi | -41,99 mln | -61,95% |
Boʻsh pul | -82,91 mln | -285,64% |
Haqida
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Tashkil etilgan
apr 2006
Sayt
Xodimlar soni
261